Novedades en la cirugía de la mama

1 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249

2 Australian Institute of Health and Welfare. Cancer data in Australia. AIHW, 2022. https://www.aihw.gov.au/repor ts/cance r/cancer-datain-austr alia/data (viewed July 2022).

3 Breast Cancer Network Australia. Breast cancer in men. BCNA, 2022. https://www.bcna.org.au/under stand ing-breast-cance r/breast-cancer-inmen (viewed July 2022).

4 Cancer Council Victoria and Department of Health Victoria. Optimal care pathway for people with breast cancer, 2nd ed. Melbourne: Cancer Council Victoria, 2021. https://www.cancer.org.au/asset s/pdf/breast-cancer-optim al-cancercare-pathway (viewed July 2022).

5 Breast Cancer Trials. The EXPERT clinical trial [website]. ANZ Breast Cancer Trials Group, 2022. https://www.breas tcanc ertri als.org.au/trial s/expert (viewed July 2022).

6 Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT —a randomised trial. Lancet 2104; 383: 603-613.

7 Cancer Australia. Guidance for the management of early breast cancer: methods. Sydney: Cancer Australia, 2020. https://www.cance raust ralia.gov.au/sites/ defau lt/files/ publi catio ns/guidance-manag ement-early-breast-cancer-metho ds/pdf/guida nce_for_the_manag ement_of_early_breast_cancer_metho ds_2020.pdf (viewed July 2022).

8 Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-2416.

9 Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.

10 Nolan E, Vaillant F, Branstetter D, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med

2016; 22: 933-939.

11 Breast Cancer Trials. The BRCA-P clinical trial  ANZ Breast Cancer Trials Group, 2022. https://www.breas tcanc ertri als.org.au/trial s/brca-p (viewed July 2022).

12 AIs recommended for breast cancer prevention. Cancer Discov 2019; 9: 311.

13 University of California, San Francisco. The WISDOM study. San Francisco: UCSF, 2021. https://www.thewi sdoms tudy.org (viewed July 2021).

14 Veenhuizen SGA, de Lange SV, Bakker MR et al. Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology 2021; 299: 278-286.

15 Weiderpass E. Lifestyle and cancer risk. J Prevent Med Pub Health 2010; 43: 459-471.

16 Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2019 [Cat. No. CAN 128]. Canberra: AIHW, 2019. https://www.aihw.gov.au/repor ts/cancer-screening/breas tscre en-austr alia-monit oringreport-2019/summary (viewed July 2022).

17 Houssami N. Overdiagnosis of breast cancer in population screening: does it make breast screening worthless? Cancer Biol Med 2017; 14:1-8.

18 Cancer Council NSW. ROSA —a roadmap for individualised breast screening [website]. Sydney: Cancer Council NSW, 2021. https://www.cance rcoun cil.com.au/news/rosa-aroadmap-for-indiv idual ised-breast-screening/#:~:text=Led%20by%20Ass ociat e%20Pro fesso r%20Car olyn%20Nic kson%2C%20the %20pro ject%2C,lives %20thr ough%20the%20ear ly%20det ectio n%20of%20bre ast%20cancer (viewed July 2022).

19 Irwig L, Macaskill P, Houssami N. Evidence relevant to the investigation of breast symptoms: the triple test. Breast 2002; 11:215-220.

20 Sogani J, Mango VL, Keating D, et al. Contrast-enhanced mammography: past, present, and future. Clin Imaging 2021; 69: 269-279.

21 Kuhl CK, Schrading S, Strobel K, et al. Abbreviated breast magnetic resonance Imaging (MRI): first postcontrast subtracted images and maximum-intensityprojection —a novel approach to breast cancer screening with MRI. J Clin Oncol 2014; 32: 2304-2310.